A5021339490- Lung Cancer Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Radiomics and Machine Learning in Medical Imaging
- Pleural and Pulmonary Diseases
- Esophageal Cancer Research and Treatment
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Gastric Cancer Management and Outcomes
- Cardiac, Anesthesia and Surgical Outcomes
- Tracheal and airway disorders
- Pancreatic and Hepatic Oncology Research
- Esophageal and GI Pathology
- Hepatocellular Carcinoma Treatment and Prognosis
- Medical Imaging Techniques and Applications
- Medical Imaging and Pathology Studies
- Metastasis and carcinoma case studies
- Bone and Dental Protein Studies
- Airway Management and Intubation Techniques
- Head and Neck Cancer Studies
- Congenital Diaphragmatic Hernia Studies
- Cancer Diagnosis and Treatment
- Colorectal Cancer Screening and Detection
- Neuroendocrine Tumor Research Advances
- Advanced Radiotherapy Techniques
- Acute Myocardial Infarction Research
Yale University
2016-2025
Yale New Haven Hospital
2017-2024
Faculty of 1000 (United States)
2023
University of New Haven
2020-2023
RELX Group (United States)
2023
University of Virginia Health System
2021
University of Michigan
2021
Yale Cancer Center
2018-2021
San Diego Cardiac Center
2020
Fistula Foundation
2020
<h3>Importance</h3> Adjuvant chemotherapy offers a survival benefit to number of staging scenarios in non–small-cell lung cancer. Variable recovery from cancer surgery may delay patient’s ability tolerate adjuvant chemotherapy, yet the urgency initiation is unclear. <h3>Objective</h3> To assess differences according time interval between resection and postoperative determine association treatment timing efficacy. <h3>Design, Setting, Participants</h3> This retrospective observational study...
In an ongoing, open-label, single-arm phase II study ( NCT02927301 ), 181 patients with untreated, resectable, stage IB-IIIB non-small cell lung cancer received two doses of neoadjuvant atezolizumab monotherapy. The primary end point was major pathological response (MPR; ≤10% viable malignant cells) in resected tumors without EGFR or ALK alterations. Of the 143 analysis, MPR 20% (95% confidence interval, 14-28%). With a minimum duration follow-up 3 years, 3-year survival rate 80%...
Background Protective ventilation may improve outcomes after major surgery. However, in the context of one-lung ventilation, such a strategy is incompletely defined. The authors hypothesized that putative protective regimen would be independently associated with decreased odds pulmonary complications thoracic Methods merged Society Thoracic Surgeons Database and Multicenter Perioperative Outcomes Group intraoperative data for lung resection procedures using across five institutions from 2012...
Purpose To compare survival rates of thermal ablation and stereotactic radiation therapy (SRT) for stage 1 non-small cell lung cancer (NSCLC). Materials Methods In this retrospective study, patients with NSCLC treated by (TA) or SRT were identified in the 2004–2013 National Cancer Database. Patients who underwent TA one-to-one propensity matched to undergo ablation. Outcomes overall unplanned hospital readmission within 30 days after treatment. Results This study included 28 834 (TA, 1102...
<h3>Importance</h3> Directing patients to safer hospitals for complex cancer surgery (regionalization) may prevent thousands of mortalities in the United States. <h3>Objective</h3> To understand potential individuals move hospitals: what would inspire them travel (motivators), challenges they face (barriers), and enable (facilitators). <h3>Design, Setting, Participants</h3> This nationally representative online survey study asked respondents consider at their local hospital or a specializing...
8541 Background: Platinum-based chemotherapy, before or after surgery, provides only a 5% benefit in 5yr. OS locally advanced NSCLC. A recent pilot study (JCO 2017 35:15suppl, 8508) showed that preoperative immune checkpoint inhibitor therapy was well tolerated and yielded clinically meaningful major pathologic response rate (MPR ≤10% residual viable tumor cells). This large multicenter trial tests the MPR novel biomarkers of using this neoadjuvant approach with atezolizumab (atezo)...
Video-assisted thoracoscopic surgery (VATS) lobectomy has been shown to be a safe, minimally invasive approach for the surgical management of lung cancer. Despite evidence supporting oncologic efficacy, recent reports indicate that less than half lobectomies are performed by VATS. We examined nationwide practice patterns identify specific predictors VATS adoption.Premier hospital data (2010 2014) were used open and procedures treatment primary Propensity score method was match operations...
As many as 55% of patients with non-small cell lung cancer (NSCLC) present stage IV disease at diagnosis. Although systemic therapy is the cornerstone for treatment these patients, growing evidence suggests that local primary tumor site may improve survival.To assess whether addition in NSCLC provides a survival benefit over alone.In this comparative effectiveness research study, National Cancer Database (NCDB; 2018 version) was retrospectively queried from January 1, 2010, through December...
ObjectiveMultimodality treatment for resectable non–small cell lung cancer has long remained at a therapeutic plateau. Immune checkpoint inhibitors are highly effective in advanced and promising preoperatively small clinical trials cancer. This large multicenter trial tested the safety efficacy of neoadjuvant atezolizumab surgery.MethodsPatients with stage IB to select IIIB Eastern Cooperative Oncology Group performance status 0/1 were eligible. Patients received 1200 mg intravenously every...
Background Interactions between immune and tumor cells are critical to determining cancer progression response. In addition, preclinical prediction of immune-related drug efficacy is limited by interspecies differences human mouse, as well inter-person germline somatic variation. To address these gaps, we developed an autologous system that models the microenvironment (TME) from individual patients with solid tumors. Method With patient-derived bone marrow hematopoietic stem progenitor...
Purpose Plasma osteopontin (OPN) levels in advanced non–small-cell lung cancer (NSCLC) correlate with therapeutic response and survival, but the utility of plasma OPN for diagnosis monitoring early-stage NSCLC has not been investigated. We hypothesize that are elevated decrease resection. Patients Methods Presurgery (in ng/mL) were measured by enzyme-linked immunosorbent assay (ELISA) a discovery set 60 patients compared data from 56 cancer-free smokers. was validated an independent cohort...
<h3>Importance</h3> Leading cancer hospitals have increasingly shared their brands with other through growing networks of affiliations. However, the brand top-ranked may evoke distinct reputations for safety and quality that do not extend to all within these networks. <h3>Objective</h3> To assess perioperative mortality Medicare beneficiaries after complex surgery across participating in hospitals. <h3>Design, Setting, Participants</h3> A cross-sectional study was performed Centers &...